Lima, Peru, Jun 15, 2004 / 22:00 pm
Peru’s Minister of Health, Pilar Mazzetti, said this week she will not reverse her decision to distribute the morning after pill, or emergency oral contraceptive, at Peruvian family planning centers and she denied the pill’s abortifacient nature on the basis of the supposed “latest” studies, which in reality are not so recent.
At the beginning of April, Mazzetti said she would await a decision of the Food and Drug Administration in the U.S. concerning the effects of the drug Levonorgestrel before determining whether to use the drug in public health programs.
In Peru the Constitution protects the unborn. The morning after pill prevents a buildup of the lining of the uterus, thus causing the death of a fertilized ovum. The FDA published their latest information on the drug on May 7, 2004, on their website at http://www.fda.gov/cder/drug/infopage/planB/planBQandA.htm.
The FDA reiterated that when consumed after fertilization has taken place, Plan B (as the drug is called in the U.S.) prevents implantation in the uterus.